中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2014年
30期
2-3
,共2页
晚期乳腺癌%培美曲塞%奈达铂%吉西他滨%疗效
晚期乳腺癌%培美麯塞%奈達鉑%吉西他濱%療效
만기유선암%배미곡새%내체박%길서타빈%료효
For advanced breast cancer%Pemetrexed%Nedaplatin%Gemcitabine%Efifcacy
目的：观察培美曲塞联合奈达铂治疗晚期乳腺癌的近期疗效及其不良反应。方法选取我院肿瘤科2013年1月至2014年5月收治的晚期乳腺癌患者42例，随机分为观察组22例和对照组20例，观察组给予培美曲塞联合奈达铂治疗，对照组给予吉西他滨联合奈达铂治疗，分别治疗2个疗程后，观察两组患者治疗有效率及不良反应。结果观察组治疗有效率为40.91%，疾病控制率为77.27%，对照组治疗有效率为40.00%，疾病控制率为75.00%，两组治疗有效率和疾病控制率比较均无明显差异（P>0.05），两组患者药物不良反应主要为白细胞减少、红细胞减少和血红蛋白减少等骨髓抑制症状，以及恶心、呕吐、脱发和肝肾功能损害等，两组药物不良反应发生率比较差异无统计学意义（P>0.05）。结论培美曲塞联合奈达铂治疗晚期乳腺癌安全有效，值得临床推广。
目的：觀察培美麯塞聯閤奈達鉑治療晚期乳腺癌的近期療效及其不良反應。方法選取我院腫瘤科2013年1月至2014年5月收治的晚期乳腺癌患者42例，隨機分為觀察組22例和對照組20例，觀察組給予培美麯塞聯閤奈達鉑治療，對照組給予吉西他濱聯閤奈達鉑治療，分彆治療2箇療程後，觀察兩組患者治療有效率及不良反應。結果觀察組治療有效率為40.91%，疾病控製率為77.27%，對照組治療有效率為40.00%，疾病控製率為75.00%，兩組治療有效率和疾病控製率比較均無明顯差異（P>0.05），兩組患者藥物不良反應主要為白細胞減少、紅細胞減少和血紅蛋白減少等骨髓抑製癥狀，以及噁心、嘔吐、脫髮和肝腎功能損害等，兩組藥物不良反應髮生率比較差異無統計學意義（P>0.05）。結論培美麯塞聯閤奈達鉑治療晚期乳腺癌安全有效，值得臨床推廣。
목적：관찰배미곡새연합내체박치료만기유선암적근기료효급기불량반응。방법선취아원종류과2013년1월지2014년5월수치적만기유선암환자42례，수궤분위관찰조22례화대조조20례，관찰조급여배미곡새연합내체박치료，대조조급여길서타빈연합내체박치료，분별치료2개료정후，관찰량조환자치료유효솔급불량반응。결과관찰조치료유효솔위40.91%，질병공제솔위77.27%，대조조치료유효솔위40.00%，질병공제솔위75.00%，량조치료유효솔화질병공제솔비교균무명현차이（P>0.05），량조환자약물불량반응주요위백세포감소、홍세포감소화혈홍단백감소등골수억제증상，이급악심、구토、탈발화간신공능손해등，량조약물불량반응발생솔비교차이무통계학의의（P>0.05）。결론배미곡새연합내체박치료만기유선암안전유효，치득림상추엄。
Objective?To?observe?the?efficacy?and?adverse?effects?of?pemetrexed?combined?Nedaplatin?therapy?advanced?breast?cancer.?Methods?Our?hospital?department?oncology?from?January?2013?to?May?2014,?42?cases?advanced?breast?cancer?patients?were?treated,?randomly?divided?into?observation?group?22?cases?and?control?group?20?cases,?observation?group?received?pemetrexed?therapy?combined?nedaplatin?the?control?group?received?gemcitabine?plus?nedaplatin?therapy,?respectively,?after?two?courses?of?treatment,?patients?were?observed?effectiveness?and?adverse?reactions.?Results?The?effective?rate?of 40.91%group therapy, disease control rate was 77.27%, the control group was 40.00%effective disease control rate was 75.00%, efifciency and disease control rate showed no signiifcant difference between the two groups(P>0.05),?the?two?groups?were?adverse?drug?reactions?were?neutropenia,?red?blood?cells?and?hemoglobin?reduction?to?reduce?symptoms?such?as?bone?marrow?suppression,?as?well?as?nausea,?vomiting,?hair?loss,?and?liver?and?kidney?dysfunction,?the incidence of adverse drug reactions the two groups showed no statistically signiifcant(P>0.05).?Conclusions?Pemetrexed?combined?Nedaplatin?safe?and?effective?treatment?of?advanced?breast?cancer,?worthy?of?promotion.
